NSE:LAURUSLABSNSEHealthcare
Laurus Labs Limited
📊 Drug Manufacturers - Specialty & Generic
Day ₹1,085
₹1,109 Overbought
52W ₹572
₹1,145 Overbought
₹1,103.70
▲ ₹13.25 (+1.22%)
Vol: 755,981 · Avg: 1,659,513
As of April 29, 2026 · 06:38 IST
COMPOSITE RISK SCORE
50 MODERATE
VAL:2/25 · FIN:13/25 · GRO:20/25 · TECH:15/25
📈 P/E RATIO
70.8x
Trailing
📖 P/B RATIO
12.4x
Price to Book
💰 EPS
₹15.59
TTM
🏛 MARKET CAP
₹59,598Cr
Large Cap
📊 ROE
8.0%
Return on Equity
📈 REV GROWTH
25.7%
YoY
🏢 Company Analysis · Laurus Labs Limited
💼 BUSINESS MODEL
  • Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally..
  • The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas..
  • It also provides biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products..
  • In addition, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field..
  • Operates in Drug Manufacturers - Specialty & Generic within the Healthcare sector.
  • Workforce of 6,167 employees.
🏰 MOAT & COMPETITION
  • Large-cap (₹59,598 Cr) — established player with meaningful market presence.
  • Profit margin of 12.5% — moderate pricing power.
  • Key competitors: Glaxosmi. Pharma, Sun Pharma.Inds., Abbott India, Biocon.
🚀 CATALYSTS
  • What Recent Developments Signal For The Laurus Labs NSEI LAURUSLABS Investment Story (Simply Wall St.)
  • How Recent Developments Are Reshaping The Laurus Labs Investment Story (Simply Wall St.)
  • Revenue growing at 26% — strong top-line momentum.
  • Earnings growth of 172% signals execution on profitability.
⚖️ ASYMMETRY CHECK
  • Analyst target range: ₹510 — ₹1,270 (mean ₹974, 14 analysts).
  • Unfavorable asymmetry — limited upside +15% vs downside -54% (0.3x).
  • P/E of 70.8x — premium valuation, growth must sustain to avoid de-rating risk.
🔭 FUTURE OUTLOOK
  • Analyst consensus: Hold (14 analysts).
  • Latest quarter earnings grew 173% YoY — positive trajectory.
✅ PROS
  • Company has been maintaining a healthy dividend payout of 19.5%
❌ CONS
  • Stock is trading at 12.4 times its book value
  • Company has a low return on equity of 10.5% over last 3 years.
VALUATION
2/25
25% WEIGHT
  • P/E at 71x
  • P/B at 12.4x
  • Analyst target: ₹974 (-11.7%)
  • 1Y return: +79.1%
FINANCIAL HEALTH
13/25
25% WEIGHT
  • ROE: 8.0%
  • Profit margin: 12.5%
  • Revenue growth: 25.7%
  • Debt/Equity: 45%
GROWTH
20/25
25% WEIGHT
  • Revenue growth: 25.7%
  • Earnings growth: 171.9%
  • Beta: 0.34
  • Sector: Healthcare
TECHNICAL
15/25
25% WEIGHT
  • RSI, MACD, MA crossovers
  • 200 DMA & 50 EMA position
  • Volume trend analysis
  • Price momentum signals
📈 Price Movement
🕯 Candlestick Chart
🎯 Price Prediction · Analyst Target Cone Source: Yahoo Finance Analyst Targets ↗
📉 Valuation Trends (at current CMP)
P/E Ratio at current CMP
721.2 553.7 386.2 218.7 51.2 '2014 '2015 '2016 '2017 '2018 '2019 '2020 '2021 '2022 '2023 '2024 '2025 TTM Mar 2014: 87.3 Mar 2015: 125.3 Mar 2016: 65.0 Mar 2017: 306.6 Mar 2018: 349.3 Mar 2019: 627.1 Mar 2020: 231.4 Mar 2021: 60.2 Mar 2022: 71.7 Mar 2023: 75.2 Mar 2024: 370.4 Mar 2025: 166.2 TTM: 70.7 70.7
💎 Valuation & Financial Metrics
P/E RATIO
70.8x
Trailing twelve months
P/B RATIO
12.4x
Price to Book value
ROE
8.0%
Return on Equity
PROFIT MARGIN
12.5%
Net profit margin
OPM
20.2%
Operating profit margin
ANALYST TARGET
₹974
Range: ₹510 - ₹1,270
Yahoo Finance ↗
PEG RATIO
N/A
Price/Earnings to Growth
EV/EBITDA
36.8x
Enterprise value ratio
CURRENT RATIO
N/A
Liquidity measure
DIVIDEND YIELD
0.15%
Annual yield
ROA
8.9%
Return on Assets
GROSS MARGIN
57.0%
Gross profit margin
INDUSTRY AVERAGES — PHARMACEUTICALS
P/E 34.7x (above avg)
P/B 5.0x (sector fair)
ROCE 22.7% (below avg)
ROE 20% (sector good)
OPM 22% (sector good)
Div Yield 0.91%
D/E <20 (sector comfort)
📋 Quarterly Performance Trend
QuarterRevenueQoQ %Net ProfitQoQ %Op. Cash FlowEBITDA Margin
Q2 FY25 ₹1,224 Cr— ₹20 Cr— N/A 14.9%
Q3 FY25 ₹1,415 Cr+15.6% ₹92 Cr+365.2% N/A 20.8%
Q4 FY25 ₹1,674 Cr+18.3% ₹234 Cr+153.2% N/A 28.1%
Q1 FY26 ₹1,570 Cr-6.2% ₹163 Cr-30.2% N/A 25.0%
Q3 FY26 ₹1,778 Cr+13.3% ₹252 Cr+54.4% N/A 27.3%
📊 Year-on-Year Trend
FYRevenueYoY %Net ProfitYoY %Op. Cash FlowYoY %
FY22 ₹4,889 Cr— ₹828 Cr— ₹911 Cr—
FY23 ₹6,014 Cr+23.0% ₹790 Cr-4.5% ₹994 Cr+9.1%
FY24 ₹5,002 Cr-16.8% ₹161 Cr-79.7% ₹666 Cr-33.0%
FY25 ₹5,508 Cr+10.1% ₹358 Cr+123.2% ₹602 Cr-9.6%
📈 Revenue vs Earnings
🎯 EPS: Estimate vs Actual
💰 How Laurus Labs Limited Makes Its Money
Revenue ₹1.8K Cr Cost of Revenue ₹695 Cr Gross Profit ₹1.1K Cr Op. Expenses ₹724 Cr Operating Inc. ₹360 Cr Tax ₹73 Cr Interest ₹39 Cr Net Income ₹252 Cr (14.2% margin) Dec 2025 · All values in ₹ Crores
🏦 Snapshot of Laurus Labs Limited's Balance Sheet
Total Assets ₹9.3K Cr Cash & Equiv.: ₹100 Cr (1.1%) Receivables: ₹2.0K Cr (21.5%) Inventory: ₹1.9K Cr (20.7%) Other Current: ₹289 Cr (3.1%) PP&E: ₹4.3K Cr (46.2%) Goodwill: ₹246 Cr (2.6%) Other Non-Curr.: ₹422 Cr (4.5%) Liab. + Equity ₹9.3K Cr Current Liab.: ₹3.5K Cr (37.9%) Long-Term Debt: ₹646 Cr (6.9%) Other Liab.: ₹548 Cr (5.9%) Equity: ₹4.6K Cr (49.3%) As of Mar 2025 · All values in ₹ Crores
💸 Looking into Laurus Labs Limited's Cash Flow
Operating CF ₹602 Cr Capital Exp. ₹641 Cr FY2025 · All values in ₹ Crores
📅 Quarterly Results Source: Screener ↗
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales +1,1821,2241,1951,4401,1951,2241,4151,7201,5701,6531,778
Expenses +1,0151,0371,0141,1981,0241,0451,1301,3001,1871,2501,298
Operating Profit167188181241171178285421382403480
OPM %14%15%15%17%14%15%20%24%24%24%27%
Other Income +422193595910276
Interest3942515049535856524039
Depreciation919398102106108106110117120121
Profit before tax4154351071823131312224270327
Tax %30%27%27%30%34%22%31%25%28%28%22%
Net Profit +27372375132093233162194252
EPS in Rs0.460.690.431.400.230.371.714.333.023.614.66
Raw PDF
📊 Profit & Loss Statement Source: Screener ↗
Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales +2,0562,2922,8324,8144,9366,0415,0415,5546,722
Expenses +1,6421,9352,2663,2623,5124,4484,2614,4995,035
Operating Profit4143575651,5521,4241,5927791,0551,686
OPM %20%16%20%32%29%26%15%19%25%
Other Income +29155231462475102
Interest80889068102165183216187
Depreciation125164187205251324385430468
Profit before tax2371202941,3011,0841,1092364841,133
Tax %29%22%13%24%23%28%29%27%
Net Profit +16894255984832793162358841
EPS in Rs3.161.764.7718.3315.4014.672.986.6415.62
Dividend Payout %9%17%10%11%13%14%27%18%
🏦 Balance Sheet Source: Screener ↗
Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital106106107107107108108108108
Reserves1,3771,4521,6632,4903,2443,9304,0034,3654,697
Borrowings +9801,0361,0791,4821,7772,0152,5772,7642,212
Other Liabilities +5547379011,6711,8401,6081,6992,0992,398
Total Liabilities3,0173,3313,7505,7516,9687,6608,3879,3369,415
Fixed Assets +1,4811,6291,7262,1712,6523,4093,8904,1234,242
CWIP16311067362813551423458541
Investments33333150124233261
Other Assets +1,3691,5891,9533,2143,4723,6513,9504,5214,371
Total Assets3,0173,3313,7505,7516,9687,6608,3879,3369,415
💰 Cash Flow Statement Source: Screener ↗
Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity +332342298347733911994666602
Cash from Investing Activity +-289-384-253-221-941-914-997-822-680
Cash from Financing Activity +-5442-45-12825530-2725039
Net Cash Flow-101-0-14727-3093-39
Free Cash Flow55-494412549346-1061
CFO/OP94%98%91%68%62%77%80%99%70%
📈 Key Financial Ratios
Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days1091011131029910096120132
Inventory Days186201201234266293222277285
Days Payable9610714415919914694158141
Cash Conversion Cycle199195170177166247224240276
Working Capital Days3-116154343594243
ROCE %16%14%8%14%40%26%23%7%9%
🏭 Industry Peers — Pharmaceuticals
#CompanyCMPP/EMkt CapROCEQtr ProfitScore
1Glaxosmi. Pharma ★₹2,37840.0₹40,27763.2%+22.8%58
2Sun Pharma.Inds.₹1,75534.7₹421,04720.2%+18.7%57
3Abbott India₹25,67535.8₹54,55946.2%+4.2%51
4Biocon₹36572.1₹59,2126.2%+1470.0%45
5Zydus Lifesci.₹91818.0₹92,36724.3%+7.7%45
6Lupin₹2,32721.4₹106,37621.3%+76.0%45
7Dr Reddy's Labs₹1,34920.2₹112,62922.7%-14.4%45
8Ajanta Pharma₹2,81434.6₹35,15832.4%+17.6%44
9Laurus Labs₹1,10570.7₹59,6549.2%+172.7%30
★ Glaxosmi. Pharma ranks higher on combined P/E, ROCE, and growth metrics in Pharmaceuticals
🏛 Shareholding Pattern
Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters27.62%27.62%27.60%27.60%27.49%27.49%
FIIs25.56%25.51%25.70%26.17%26.52%25.82%
DIIs12.74%11.78%11.94%11.72%12.42%13.96%
Public34.09%35.09%34.78%34.52%33.57%32.73%
No. of Shareholders2,92,2142,92,9052,80,2232,83,6782,80,7562,92,281
🟢 CATALYSTS
🏆Revenue Growth 26%: Above sector norm of 25% — strong top-line momentum.
💹Low Beta (0.34): Less volatile than market — defensive play.
🔀Earnings Growth (172%): Above sector norm — strong profit expansion.
🔴 RISKS
📜Elevated P/E (70.8x): Above sector expensive threshold of 50x.
💰Below Analyst Target: CMP above mean target — limited upside consensus.
🔓Market Risk: Broader market correction or sentiment shift could impact stock.
🕸 Factor Analysis · Radar
Momentum 6/10: 1M +11.2%, 6M +14.9%, RSI 55, MACD bearish, Above 200DMA Sentiment 3/10: Analyst upside -11.7%, Rec: hold Value 1/10: P/E 70.8, P/B 12.4, EV/EBITDA 36.8 Quality 5/10: Margin 12.5%, D/E 45 Low Volatility 9/10: Beta 0.34, Ann. vol 29% Momentum 6 Sentiment 3 Value 1 Quality 5 Low Vol 9
Momentum 6/10
1M +11.2%, 6M +14.9%, RSI 55, MACD bearish, Above 200DMA
Sentiment 3/10
Analyst upside -11.7%, Rec: hold
Value 1/10
P/E 70.8, P/B 12.4, EV/EBITDA 36.8
Quality 5/10
Margin 12.5%, D/E 45
Low Volatility 9/10
Beta 0.34, Ann. vol 29%
🎯 Decision Matrix
ActionIf Stock RisesIf Stock Falls
BUYBenefit from potential re-ratingOPM of 20% provides margin buffer; P/E 71x vs sector median 35x is a risk
HOLDRetain existing position; wait for better entry; FII stake falling (-0.70%)Miss further upside if momentum continues; 1M return of +11.2% shows momentum
SELLLock in +79.1% 1Y return; redeploy into Glaxosmi. Pharma at lower P/EAvoid further drawdown; P/E compression risk at 71x
REASONS TO BUY
  • Revenue growing at 25.7% YoY (sector norm: 10%)
REASONS TO SELL / AVOID
  • P/E of 70.8x is 2.0x the sector median of 35x
  • FII stake falling (-0.70%) — institutional exit signal
  • Glaxosmi. Pharma offers lower P/E (40.0) with ROCE of 63.2% in the same sector
  • 1Y return of +79.1% — profit booking opportunity
📰 Latest News
What Recent Developments Signal For The Laurus Labs NSEI LAURUSLABS Investment Story
Simply Wall St. · 2026-02-04T13:23
Laurus Labs Ltd (BOM:540222) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and ...
GuruFocus.com · 2026-01-23T19:01
Reframing The Story For Laurus Labs (NSEI:LAURUSLABS) After The New Fair Value Reset
Simply Wall St. · 2026-01-21T05:23
How Recent Developments Are Reshaping The Laurus Labs Investment Story
Simply Wall St. · 2025-12-08T03:11
How the Narrative Around Laurus Labs Is Shifting After Recent Analyst Updates
Simply Wall St. · 2025-11-23T08:12
Why The Narrative Around Laurus Labs Is Shifting After Recent Analyst and Dividend Updates
Simply Wall St. · 2025-11-05T15:13
RECOMMENDATION
HOLD
COMPOSITE SCORE
50/100
Laurus Labs Limited trades at ₹1,103.70 with a composite risk score of 50/100. The stock scores 2/25 on valuation, 13/25 on financial health, 20/25 on growth, and 15/25 on technicals. The company is currently profitable with moderate return on equity.

The stock is trading near or above analyst consensus targets. Revenue growth is at 25.7% — a strong positive signal.

Within Pharmaceuticals, Glaxosmi. Pharma (P/E 40.0, ROCE 63.2%) ranks higher on techno-fundamental metrics and may be worth considering.

Bottom Line: Neutral for Healthcare — wait for better entry or catalyst. The current recommendation is HOLD.
PROFITABLE STRONG GROWTH EXPENSIVE
RISK SCORE REPORT · NSE:LAURUSLABS · GENERATED APR 29, 2026 06:38 IST · DATA VIA YAHOO FINANCE + SCREENER.IN
DISCLAIMER: THIS IS NOT FINANCIAL ADVICE. DATA MAY BE DELAYED. ALWAYS VERIFY WITH OFFICIAL SOURCES BEFORE INVESTING.